Mollyann Brodie Receives AAPOR Award for Exceptionally Distinguished Achievement
The American Association of Public Opinion Research (AAPOR) recognized KFF’s Mollyann Brodie, Ph.D., with the…
Mollyann Brodie Receives AAPOR Award for Exceptionally Distinguished Achievement
The American Association of Public Opinion Research (AAPOR) recognized KFF’s Mollyann Brodie, Ph.D., with the AAPOR Award for Distinguished Achievement for her outstanding leadership and contributions to the field of public opinion research over three decades. Also, KFF’s Surveys of Immigrants received the 2026 AAPOR Inclusive Voices Award, which recognizes work examining complex challenges related…
Private Voice AI in Healthcare: How to Capture Critical Conversations Without Letting Patient Data Leave the Building
When deployed within the organization’s own infrastructure, voice AI unlocks these four concrete benefits for healthcare teams. The post Private Voice AI in Healthcare: How to Capture Critical Conversations Without Letting Patient Data Leave the Building appeared first on MedCity News.
Federal Vaccine Injury Compensation Programs: Overview and Current Issues
This brief summarizes the history, rationale, and policy issues related to the federal government’s key vaccine injury compensation programs, known as the Vaccine Injury Compensation Program (VICP) and Countermeasures Injury Compensation Program (CICP).
Four Reasons ECMO Programs Stall
ECMO is specialized enough that the learning curve carries real clinical and financial consequences, and there is no shortcut to the institutional knowledge that takes years to accumulate. The post Four Reasons ECMO Programs Stall appeared first on MedCity News.
The Current “SaaS Meltdown” Will Fundamentally Change the Tech Stack by 2027
Healthcare leaders must recognize this impending shift now and get ready for it by changing how they evaluate technology and the operational tasks they expect it to solve. The post The Current “SaaS Meltdown” Will Fundamentally Change the Tech Stack by 2027 appeared first on MedCity News.
FDA Blocked Melanoma Drug as Confusion Reigned Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw that the drug had prolonged the lives of a third of the participants in a clinical trial. “It was devastating news,” said Trisha Wise-Draper, a dermatologist at the University…
Minnesota Lawmaker Proposes Using Hospital Tax To Fill Charity Care Gap
Minnesota lawmakers are wrestling with how to sustain the state’s financially distressed hospitals while patients confront growing medical debt. One Minnesota lawmaker wants to steer money from an existing healthcare tax back to hospitals so they can expand their charity care programs for patients who can’t afford their bills. The proposal follows a Minnesota Star…
Kennedy, Balancing MAHA and White House, Says He Won’t Run for President in 2028
Health and Human Services Secretary Robert F. Kennedy Jr. is caught between his Make America Healthy Again supporters who want him to do more to advance their priorities, including curtailing vaccines, and a White House trying to combat President Donald Trump’s unpopularity. Protesters’ chants could be heard from inside the Cleveland City Club, where Kennedy…
Shyld AI Snags $13M for Device that Disinfects Hospital Rooms Autonomously
Shyld AI has raised $13.4 million to expand its AI-powered UV disinfection platform, which autonomously sanitizes hospital rooms. The startup’s technology aims to reduce the risk of hospital-acquired infection, as well as lessen hospitals’ reliance on labor-intensive cleaning workflows. The post Shyld AI Snags $13M for Device that Disinfects Hospital Rooms Autonomously appeared first on…
FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer Drug
BeOne Medicines drug Beqalzi has accelerated FDA approval for treating relapsed or refractory mantle cell lymphoma, a type of blood cancer. The regulatory nod opens the door to potentially compete against Venclexta, a blockbuster cancer drug marketed by AbbVie and Roche. The post FDA Approval Gives BeOne Medicines a New Challenger to AbbVie, Roche Cancer…
